Revna Biosciences (www.RevnaBio.com) has carved a niche for itself in Ghana and West Africa by being the first facility in the region to secure dual ISO accreditations: ISO 15189:2022 for clinical diagnostics and ISO 20387:2018 for biobanking. This milestone is a testament to RevnaBio’s unwavering commitment to championing precision medicine by propelling molecular diagnostics and therapeutic discovery in the region.
A Pledge to Quality and Patient Care
The American Association for Laboratory Accreditation (A2LA) has bestowed the ISO 15189:2022 accreditation upon Revna Biosciences, acknowledging its dedication to delivering top-tier clinical testing services. The accreditation process entailed a rigorous on-site evaluation by A2LA’s assessors, verifying the facility’s compliance with strict standards of precision, reliability, and patient confidentiality.
Revna Biosciences’ accreditation encompasses an extensive array of human sample tests, including those involving urine, swabs, blood, bone marrow, tissue samples, and plasma. With a specialization in bacteriology, virology, and molecular pathology,…